Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical tr... Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.73 | -5.62403697997 | 12.98 | 13.82 | 12.07 | 707864 | 12.82600983 | DE |
| 4 | -1.4 | -10.2564102564 | 13.65 | 14.58 | 12.07 | 412460 | 13.18606164 | DE |
| 12 | -0.13 | -1.05008077544 | 12.38 | 14.72 | 11.68 | 344224 | 12.92916297 | DE |
| 26 | -7.33 | -37.4361593463 | 19.58 | 21.04 | 11 | 418311 | 13.58328624 | DE |
| 52 | -0.36 | -2.85487708168 | 12.61 | 22.985 | 11 | 439894 | 16.16977921 | DE |
| 156 | 0.36 | 3.02775441548 | 11.89 | 170.09 | 8.61 | 511640 | 15.38020483 | DE |
| 260 | 10.8 | 744.827586207 | 1.45 | 170.09 | 1.445 | 453760 | 12.82992193 | DE |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
